Aileron Therapeutics' Investigational Drug Shows Encouraging Action In Lung Fibrosis

By Yahoo! Finance | Nov 13, 2024 at 01:04 PM EST

Aileron Therapeutics released positive Phase 1b trial data for inhaled LTI-03 in treating IPF. Results showed potential to improve lung function and reverse IPF progression without inducing inflammation. Stock price of ALRN was down 5.48% to $3.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.